U.S. Markets open in 4 hrs 4 mins

Regeneron Could Benefit From 'Lackluster' Data Presented By These Rivals

ALLISON GATLIN
Regeneron Could Benefit From 'Lackluster' Data Presented By These Rivals

Regeneron should benefit after Novartis and Roche presented data for competitors to blockbuster eye drug Eylea.